RHEACELL GmbH & Co. KG
11
0
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
27.3%
3 terminated/withdrawn out of 11 trials
57.1%
-29.4% vs industry average
27%
3 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
Role: lead
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
Role: lead
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)
Role: lead
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
Role: lead
Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD
Role: lead
Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa
Role: lead
Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure
Role: lead
Allogeneic ABCB5-positive Stem Cells for Treatment of DFU "Malum Perforans"
Role: lead
Allogeneic ABCB5-positive Stem Cells for Treatment of CVU
Role: lead
Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers
Role: lead
Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD
Role: lead
All 11 trials loaded